1
|
Zhang J, Li Y, Gong Y, Zhu C, Zhang L, Tang H, He W, Wang B. Bi(Ⅲ) and Ce(Ⅳ) functionalized carbon nitride photocatalyst for antibiotic degradation: Synthesis, toxicity, and mechanism investigations. CHEMOSPHERE 2023; 333:138888. [PMID: 37209849 DOI: 10.1016/j.chemosphere.2023.138888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 04/28/2023] [Accepted: 05/06/2023] [Indexed: 05/22/2023]
Abstract
Graphite-phase carbon nitride (g-C3N4) has shown great potential for antibiotic wastewater treatment due to its unique electronic structure and corresponding to visible light. In this study, a series of Bi/Ce/g-C3N4 photocatalysts with different doping amount were developed by direct calcination method for Rhodamine B and sulfamethoxazole photocatalytic degradation. The experiment result shows that the photocatalytic performance of Bi/Ce/g-C3N4 catalysts were better than that of single component samples. Under the optimal experimental conditions, the degradation rates of RhB (20 min) and SMX (120 min) by 3Bi/Ce/g-C3N4 reached 98.3% and 70.5%, respectively. The theoretical calculation results of DFT show that after Bi and Ce doping modification, the band-gap width of g-C3N4 is reduced to 1.215 eV and carrier migration rate is greatly improved. The enhanced photocatalytic activity was mainly attributed to the capture of electrons after doping modification, which inhibition of photogenerated carriers recombination and reduced the gap width. The cyclic treatment experiment of sulfamethoxazole showed that Bi/Ce/g-C3N4 catalysts had good stability. Ecosar evaluation and leaching toxicity test showed that Bi/Ce/g-C3N4 can be safely used for wastewater treatment. This study provides a perfect strategy for modifying g-C3N4 and a new way to improve the photocatalytic performance.
Collapse
Affiliation(s)
- Jian Zhang
- College of Chemical Engineering, Northeast Electric Power University, Jilin, 132012, PR China(2).
| | - Yuanchun Li
- College of Chemical Engineering, Northeast Electric Power University, Jilin, 132012, PR China(2)
| | - Yuanyi Gong
- College of Chemical Engineering, Northeast Electric Power University, Jilin, 132012, PR China(2)
| | - Chuntao Zhu
- College of Chemical Engineering, Northeast Electric Power University, Jilin, 132012, PR China(2)
| | - Lanhe Zhang
- College of Chemical Engineering, Northeast Electric Power University, Jilin, 132012, PR China(2)
| | - Hong Tang
- College of Chemical Engineering, Northeast Electric Power University, Jilin, 132012, PR China(2)
| | - Weihua He
- State Key Laboratory of Urban Water Resource and Environment, School of Environment, Harbin Institute of Technology, Harbin, 150090, PR China(2).
| | - Bing Wang
- College of Chemical Engineering, Northeast Electric Power University, Jilin, 132012, PR China(2)
| |
Collapse
|
2
|
Ueda T, Takesue Y, Nakajima K, Ichiki K, Ishikawa K, Yamada K, Tsuchida T, Otani N, Takahashi Y, Ishihara M, Takubo S, Iijima K, Ikeuchi H, Uchino M, Kimura T. Correlation between Antimicrobial Resistance and the Hospital-Wide Diverse Use of Broad-Spectrum Antibiotics by the Antimicrobial Stewardship Program in Japan. Pharmaceutics 2023; 15:pharmaceutics15020518. [PMID: 36839839 PMCID: PMC9964530 DOI: 10.3390/pharmaceutics15020518] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 01/21/2023] [Accepted: 01/30/2023] [Indexed: 02/09/2023] Open
Abstract
Increased antibiotic use and antibiotic homogeneity cause selective pressure. This study investigated the correlation between antibiotic diversity and antimicrobial resistance (AMR) in Gram-negative organisms. The days of therapy/100 patient-days (DOT) for four broad-spectrum antibiotic classes were evaluated for 2015-2022. The antibiotic heterogeneity index (AHI) for the equal use of four classes (25%) and the modified AHI for the equal use of three classes (30%), excluding fluoroquinolones (10%), were measured (target: 1.0). Quarterly antibiotic use markers and the resistance rates against ≥2 anti-Pseudomonas antibiotics were compared. The DOT value was 9.94, and the relative DOT were 34.8% for carbapenems, 32.1% for piperacillin/tazobactam, 24.3% for fourth generation cephalosporins/ceftazidime/aztreonam, and 8.9% for fluoroquinolones. Although no correlation was found between the total DOT and the resistance rate for any bacterium, a significant negative correlation was found between the heterogeneity indices and resistance rates for Pseudomonas aeruginosa and Klebsiella pneumoniae. The significant cutoffs that discriminate the risk of resistance were 0.756 for the AHI and 0.889 for the modified AHI for K. pneumoniae. Antibiotic diversity is more important in preventing AMR than overall antibiotic use. The ideal ratio of broad-spectrum antibiotics should be studied for diversified use to prevent AMR.
Collapse
Affiliation(s)
- Takashi Ueda
- Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya 663-8501, Hyogo, Japan
| | - Yoshio Takesue
- Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya 663-8501, Hyogo, Japan
- Department of Clinical Infectious Diseases, Tokoname City Hospital, Tokoname 479-8510, Aichi, Japan
- Correspondence: ; Tel.: +81-0798-45-6689; Fax: +81-0798-45-6769
| | - Kazuhiko Nakajima
- Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya 663-8501, Hyogo, Japan
| | - Kaoru Ichiki
- Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya 663-8501, Hyogo, Japan
| | - Kaori Ishikawa
- Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya 663-8501, Hyogo, Japan
| | - Kumiko Yamada
- Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya 663-8501, Hyogo, Japan
| | - Toshie Tsuchida
- Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya 663-8501, Hyogo, Japan
| | - Naruhito Otani
- Department of Public Health, Hyogo College of Medicine, Nishinomiya 663-8501, Hyogo, Japan
| | - Yoshiko Takahashi
- Department of Pharmacy, Hyogo College of Medicine Hospital, Nishinomiya 663-8501, Hyogo, Japan
| | - Mika Ishihara
- Department of Pharmacy, Hyogo College of Medicine Hospital, Nishinomiya 663-8501, Hyogo, Japan
| | - Shingo Takubo
- Department of Pharmacy, Hyogo College of Medicine Hospital, Nishinomiya 663-8501, Hyogo, Japan
| | - Kosuke Iijima
- Department of Clinical Technology, Hyogo College of Medicine, Nishinomiya 663-8501, Hyogo, Japan
| | - Hiroki Ikeuchi
- Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Nishinomiya 663-8501, Hyogo, Japan
| | - Motoi Uchino
- Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Nishinomiya 663-8501, Hyogo, Japan
| | - Takeshi Kimura
- Department of Pharmacy, Hyogo College of Medicine Hospital, Nishinomiya 663-8501, Hyogo, Japan
| |
Collapse
|
3
|
Ye D, Yang C, Ji W, Zheng J, Zhang J, Xue R, Gu J, Chen M, Yan K, Liu Y. Impact of the Expert Consensus on Carbapenem Consumption Trends and Patterns in Public Healthcare Institutes: An Interrupted Time Series Analysis, 2017-2020. Front Pharmacol 2022; 12:739960. [PMID: 35095482 PMCID: PMC8793738 DOI: 10.3389/fphar.2021.739960] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Accepted: 12/27/2021] [Indexed: 01/14/2023] Open
Abstract
Background: Carbapenems are considered the last line of defence against bacterial infections, but their high consumption and the resulting antibacterial resistance are an increasing global concern. In this context, the Chinese health authority issued an expert consensus on the clinical applications of carbapenems. However, the long- and short-term effects of the expert consensus on carbapenem use are not clear. Methods: This study was conducted in Shaanxi, a northwest province of China. We collected all available carbapenem procurement data between January 2017 and December 2020 from the Provincial Drug Centralized Bidding Procurement System. A quasi-experimental interrupted time series analysis was used to evaluate the longitudinal effectiveness of expert consensus by measuring the change in the Defined Daily Dosesper 1,000 inhabitants per day (DID), the percentage of carbapenem expenditures to total antimicrobial expenditure, the total carbapenem expenditure, and the defined daily cost (DDDc). We used Stata SE version 15.0 for data analysis, and p < 0.05 was considered statistically significant. Results: After the distribution of the expert consensus, the level (p = 0.769) and trend (p = 0.184) of DID decreased, but the differences were not statistically significant. The percentage of carbapenem expenditures to total antimicrobial expenditure decreased abruptly (p < 0.001) after the intervention, but the long-term trend was still upward. There was no statistically significant relationship between the release of the expert consensus and carbapenem expenditure in the long term, but there was a decreasing trend (p = 0.032). However, the expert consensus had a positive impact on the economic burden of carbapenem usage in patients, as the level (p < 0.001), and trend (p = 0.003) of DDDc significantly decreased. Conclusion: The long-term effects of the distribution of the expert consensus on the use and expenditure of carbapenems in public health institutions in Shaanxi Province were not optimal. It is time to set up more administrative measures and scientific supervision to establish a specific index to limit the application of carbapenems.
Collapse
Affiliation(s)
- Dan Ye
- Department of Pharmacy, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, China.,Xi'an Key Laboratory of Cardiovascular and Cerebrovascular Diseases, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Northwest University, Xi'an, China
| | - Caijun Yang
- Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China
| | - Wenjing Ji
- Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China
| | - Jie Zheng
- Department of Pharmacy, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, China.,Xi'an Key Laboratory of Cardiovascular and Cerebrovascular Diseases, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Northwest University, Xi'an, China
| | - Jingyi Zhang
- Department of Pharmacy, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, China.,Xi'an Key Laboratory of Cardiovascular and Cerebrovascular Diseases, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Northwest University, Xi'an, China
| | - Runqing Xue
- Department of Pharmacy, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, China.,Xi'an Key Laboratory of Cardiovascular and Cerebrovascular Diseases, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Northwest University, Xi'an, China
| | - Jianli Gu
- Department of Pharmacy, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, China.,Xi'an Key Laboratory of Cardiovascular and Cerebrovascular Diseases, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Northwest University, Xi'an, China
| | - Minchun Chen
- Department of Pharmacy, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, China.,Xi'an Key Laboratory of Cardiovascular and Cerebrovascular Diseases, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Northwest University, Xi'an, China
| | - Kangkang Yan
- Department of Pharmacy, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, China.,Xi'an Key Laboratory of Cardiovascular and Cerebrovascular Diseases, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Northwest University, Xi'an, China
| | - Yongzhong Liu
- Department of Pharmacy, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, China.,Xi'an Key Laboratory of Cardiovascular and Cerebrovascular Diseases, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Northwest University, Xi'an, China
| |
Collapse
|